Loading organizations...
§ Private Profile · 10600 N. Tantau Ave. Cupertino, CA 95014-0739
Medical device developer creating tools for surgeons performing less invasive cardiac surgery, focused on CABG.
Key people at CardioThoracic Systems.
CardioThoracic Systems was a medical device company based in Cupertino, California, that developed innovative surgical tools to enable less invasive cardiac procedures, specifically coronary artery bypass grafting on a beating heart. The organization manufactured specialized equipment for the cardiac surgery sector, including the proprietary OPCAB and MIDCAB access platforms and stabilizer systems targeted directly at surgeons performing these complex operations. In 1999, the enterprise agreed to be acquired by Guidant Corporation, led by president and chief executive officer Ronald Dollens, in a major transaction valued at 313 million dollars. This acquisition priced the medical device manufacturer at nineteen dollars and fifty cents per share and was projected to close in the fourth quarter before becoming accretive to earnings by 2001. The specific founding year and original founders of the enterprise remain publicly undisclosed within available historical data.
Key people at CardioThoracic Systems.
CardioThoracic Systems is a medical device company founded in 1994 and based in Cupertino, California, specializing in minimally invasive beating heart surgery technologies.[1][2][3] It developed instruments and procedures to advance coronary artery bypass graft (CABG) surgery, enabling operations on a beating heart to reduce risks associated with stopping the heart.[1][4][5][6] The company targeted cardiac surgeons and hospitals performing heart surgeries, addressing the problem of complications from traditional methods that require cardiopulmonary bypass. It received early-stage investment from NEA in 1995 and went public in November 1999 under ticker CTSI, though search results do not detail later financials or current status.[1][2][6]
Founded in 1994 in Cupertino, California, CardioThoracic Systems emerged during the rise of minimally invasive cardiac procedures.[1][2] Key details on specific founders are not available in sources, but the company quickly attracted venture capital, with NEA making its first investment in 1995 in the early stage.[6] A pivotal moment came with the development of its beating heart surgery system, which aimed to simplify off-pump CABG procedures. By 1999, it had achieved sufficient traction to go public, marking rapid evolution from startup to publicly traded entity amid growing demand for less invasive heart surgeries.[1][2]
CardioThoracic Systems rode the 1990s trend toward minimally invasive surgery, capitalizing on market forces like rising CABG volumes and surgeon demand for off-pump techniques to minimize bypass risks.[1][4][6] Timing was ideal post-early '90s advancements in endoscopic tools, positioning it amid healthcare shifts toward cost-effective, patient-friendly procedures. It influenced the cardiac device ecosystem by validating beating heart approaches, paving the way for later medtech innovations in robotics and stabilizers from competitors.[1]
With its public listing in 1999, CardioThoracic Systems appeared poised for scaling amid medtech growth, but limited recent data suggests it may have been acquired or wound down—common for era-specific device firms facing patent cliffs or competition.[1] Future trends like AI-assisted surgery and expanded off-pump adoption could revive similar tech, potentially evolving its legacy through IP licensing. Its story underscores early movers in cardiac innovation, tying back to pioneering tools that made beating heart surgery viable for modern practice.[4][5][6]
